Zhongtai International: Maintains a buy rating on Sino Biopharmaceutical (01801.HK) with a target price of 134.50 Hong Kong dollars.

According to the Wisdom Finance app, Zhongtai International released a research report stating that the target price of Sino Biopharmaceutical (01801.HK) has been adjusted to HK$134.50, reiterating a "buy" rating. Due to the rapid increase in the company's core business pharmaceutical product sales revenue and the expected further implementation of licensing fees for overseas collaboration projects, the company is worth paying attention to. The bank has raised its forecast for pharmaceutical product sales revenue, expecting a year-on-year increase of 34.6%, 24.5%, and 24.9% for 2026-28E product sales revenue respectively.